From the journals: MCP
Targeting sANPEP in brain disease. A new insight for treating renal cancer. Read about articles on these topics recently published in the journal Molecular & Cellular Proteomics.
Targeting sANPEP in brain disease
Neuroinflammation, a response to cellular injury in the brain or spinal cord, helps the immune system and the brain communicate by recruiting cytokines and chemokines and also plays a role in neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases, multiple sclerosis and amyotrophic lateral sclerosis.
Complex integral activity among cells in the central nervous system, or CNS, including neurons and glia cells, causes neuroinflammation. The macroglial cells known as astrocytes, the most abundant and diverse nonneuronal cells in the CNS, are major regulators of neuroinflammation. Microglia, an integrative part of the CNS system, are nonneuronal cells that regulate the innate immune response of the brain. The crosstalk between microglia and astrocytes supports neuronal function and survival after acute CNS injury or disease, and this communication is maintained via secreted growth factors, cytokines, chemokines and innate-immunity mediators.
A recent Molecular & Cellular Proteomics article by Jong-Heon Kim and a team from Korea and the U.S. focuses on how the brain renin–angiotensin system, or RAS, regulates the astrocyte–microglia crosstalk by analysing the astrocyte secretome, which provides information about secreted proteins and their pathways.
The researchers identified a markedly elevated level of a soluble form of aminopeptidase N called sANPEP, a RAS component in the secretome, during neuroinflammation. They identified 322 proteins by proteomic analysis in astrocyte-conditioned medium following inflammatory stimulation. When they analyzed the proteins’ functional distribution, they found sANPEP was one of the upregulated proteins in RAS that is related to inflammation-associated pathways in activated astrocytes. They also found a significantly higher sANPEP level in the plasma of mice genetically altered for neuroinflammation than in unaltered mice.
This work helps identify sANPEP as a biomarker in disorders such as Alzheimer’s disease, because it is upregulated in the body fluid and human astrocytes in a neuroinflammation model. Its enzymatic activity to promote microglial stimulation indicates therapeutic potential as a drug target.
An insight for treating renal cancer
About 5% to 10% of all known cancer types are hereditary. These cancers, linked to gene mutations passed from parents to their offspring, are often difficult to treat.
Birt–Hogg–Dubé, or BHD, syndrome, a rare autosomal dominant inherited disorder, often precedes development of renal cell carcinoma, or RCC. In 2002, researchers identified a germline mutation in the folliculin gene, or FLCN, as a factor for BHD development. Since this discovery, multiple research groups have tried to understand how FLCN functions in RCC.
In a recently published Molecular & Cellular Proteomics article, Iris Glykofridis and a team in the Netherlands delved into the phosphorylated kinase pathway to understand how FLCN suppresses renal tumorigenesis. They investigated the role of FLCN in the cellular signaling pathway via protein and receptor phosphorylation by analyzing phosphoproteomic profiles of human renal tubular epithelial cells with and without FLCN. They identified specific tyrosine phosphorylation sites with markedly higher levels of phosphorylation in major receptor tyrosine kinases like EGFR and significant dephosphorylation in transcription factor EB phosphoserines upon FLCN loss.
The researchers analyzed the phosphoproteomic data and showed that FLCN loss has a clear effect on the phosphorylation of kinases and substrates within multiple biological pathways and may be important for the onset of oncogenic transformation of renal cells. The authors hope that understanding the FLCN-dependent phosphorylation pathway can open a new window to help design novel candidates for targeted therapies.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
The quest to treat and cure xerostomia
Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.
There's more to blue cheese than just the stench
Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.
Engineering cells to broadcast their behavior can help scientists study their inner workings
Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.
From the journals: JBC
Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.
Seeking the sweet spot to beat a pig parasite
Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.
Radioactive drugs strike cancer with precision
The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.